Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Sell

C

Repligen Corp (RGEN)

Biological Products, (no Disgnostic Substances)

https://www.repligen.com

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

41 SEYON STREET, BUILDING 1, SUITE 100
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/29/1986

Market Cap

8,290,082,130

Shares Outstanding

55,830,000

Weighted SO

55,832,013

Total Employees

N/A

Upcoming Earnings

07/30/2024

Similar Tickers

ISRG --.--%

RMD --.--%

MMSI --.--%

ICUI --.--%

COO --.--%

WST --.--%

BDX --.--%

HOLX --.--%

TFX --.--%

Beta

0.9520

Last Div

0.0000

Range

110.45-211.13

Chg

-14.5900

Avg Vol

809083

Mkt Cap

8290082130

Exch

NASDAQ

Country

US

Phone

781 250 0111

DCF Diff

56.9382

DCF

86.4968

Div Yield

0.0000

P/S

13.7628

EV Multiple

312.8224

P/FV

4.1644

Div Yield %

0.0000

P/E

-4351.3675

PEG

-147.7114

Payout

-0.1599

Current Ratio

6.6487

Quick Ratio

5.5557

Cash Ratio

4.6421

DSO

74.6810

DIO

196.1929

Op Cycle

270.8739

DPO

21.5317

CCC

249.3422

Gross Margin

0.4115

Op Margin

0.0156

Pretax Margin

0.0169

Net Margin

-0.0032

Eff Tax Rate

1.1868

ROA

-0.0007

ROE

-0.0012

ROCE

0.0035

NI/EBT

-0.1868

EBT/EBIT

1.0813

EBIT/Rev

0.0156

Debt Ratio

0.2094

D/E

0.3017

LT Debt/Cap

0.2068

Total Debt/Cap

0.2318

Int Coverage

-3.6406

CF/Debt

0.2589

Equity Multi

1.4408

Rec Turnover

4.8875

Pay Turnover

16.9517

Inv Turnover

1.8604

FA Turnover

1.7925

Asset Turnover

0.2105

OCF/Share

2.7771

FCF/Share

2.1340

Cash/Share

28.9581

OCF/Sales

0.2576

FCF/OCF

0.7684

CF Coverage

0.2589

ST Coverage

1.9017

CapEx Coverage

4.3185

Div&CapEx Cov

4.2823

P/BV

4.1644

P/B

4.1644

P/S

13.7628

P/E

-4351.3675

P/FCF

69.5144

P/OCF

53.3007

P/CF

53.3007

PEG

-147.7114

P/S

13.7628

EV Multiple

312.8224

P/FV

4.1644

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 09, 00:30 Chromatography System Market to Reach US$ 2.62 Billion with 6.6% CAGR by 2034 | Fact.MR Report The Motley Fool Jan 11, 04:26 How Good Is Your Market Cap Knowledge? The Motley Fool Jan 11, 04:26 How Good Is Your Market Cap Knowledge? GlobeNewswire Inc. Dec 19, 07:30 Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Dec 07, 07:30 Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements Benzinga Dec 04, 15:00 The Latest Analyst Ratings for Repligen GlobeNewswire Inc. Nov 14, 14:01 UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report GlobeNewswire Inc. Nov 14, 07:30 Repligen Announces Publication of the Company’s 2022 Sustainability Report GlobeNewswire Inc. Nov 07, 07:30 Repligen Corporation to Present at Upcoming Investor Conferences Benzinga Nov 02, 12:00 Analyst Expectations for Repligen's Future Benzinga Nov 01, 13:00 Keybanc Maintains Overweight Rating for Repligen: Here's What You Need To Know Zacks Investment Research Nov 01, 11:46 Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat Benzinga Oct 31, 12:32 Repligen's Strong Q3 Recovery: CEO Says Pharma Orders Rebound, Analytics Business Grows GlobeNewswire Inc. Oct 31, 07:30 Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Revenue Product Segmentation